Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 4/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7810455 | 0.83 | GRIN2B (0.46) | S1PR1S1PR5 | |
| SCHEMBL13008930 | 0.81 | S1PR4 (0.45) | S1PR1S1PR5SMN1; SMN2S1PR3S1PR4 | |
| SCHEMBL31643673 | 0.79 | CYP19A1 (0.47) | ALDH1A1HTT | |
| SCHEMBL21093397 | 0.74 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL21093634 | 0.73 | GRIN2B (0.44) | ALDH1A1 | |
| SCHEMBL31276928 | 0.72 | GBA1 (0.43) | ALDH1A1TP53 | |
| SCHEMBL26144434 | 0.71 | AKR1C3 (0.51) | ALDH1A1 | |
| SCHEMBL2993003 | 0.71 | ALDH1A1 (0.50) | S1PR1S1PR5ALDH1A1SMN1; SMN2PLK1 | |
| SCHEMBL2993000 | 0.71 | ALDH1A1 (0.50) | S1PR1S1PR5ALDH1A1SMN1; SMN2PLK1 | |
| SCHEMBL2993005 | 0.71 | ALDH1A1 (0.50) | S1PR1S1PR5ALDH1A1SMN1; SMN2PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | S1PR1 2931/4885S1PR5 3177/4885ALDH1A1 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.